Clinical features alone may not show the whole picture
Although biopsies provide important information, they sample very small areas of the prostate and may incorrectly represent true prostate pathology.2 The Oncotype DX GPS assay is designed to provide detailed information to more confidently assess risk and guide treatment decisions for your low-, intermediate-, and high-risk prostate cancer patients.
Prostate cancer case study with the Oncotype DX® GPS™ test
See how the Oncotype DX Genomic Prostate Score test revealed aggressive tumor biology for a patient who initially seemed like a strong candidate for active surveillance.
Rigorous development and clinical validation
The Oncotype DX Genomic Prostate Score was developed in collaboration with the Cleveland Clinic and UCSF to specifically address the many challenges inherent to prostate cancer risk assessment.3-4
The genes in the Oncotype DX GPS assay were chosen for their:
- Correlation with tumor aggressiveness regardless of multifocality or heterogeneity
- Performance in biopsy samples with small tumor volume
Multiple biologic pathways were more predictive than any single pathway alone3
View Gene List
Genetic testing vs. Genomic testing
Genetic tests typically screen for inherited risk factors or spontaneously arising mutations. They can help identify the risk of getting cancer or how a tumor will respond to certain therapies.1
Genomic tests examine gene expression levels within a sample of tumor tissue. They provide information about the tumor’s biology and aggressiveness.1